Film #1 is 1 hour and 48 minutes long. Here is the 3 minute opening scene you can preview first. But beware, because like an addictive book you cannot put down or get to the next page fast enough, this scene may move you so deeply that you will be compelled to watch the entire film!

Burzynski: Cancer Is Serious Business

Now, Part 2 has been released, and for a limited time this film can be viewed free:

BURZYNSKI: CANCER IS SERIOUS BUSINESS, PART II (2013)

In the compelling follow-up to the internationally award-winning documentary, Burzynski, the Movie; Burzynski: Cancer is Serious Business, Part II explores the current status of Antineoplastons’ clinical testing sanctioned by the United States Food & Drug Administration—and features a modern story of the struggling journeys of cancer patients being treated today at the Burzynski Clinic in Houston, Texas.

For most patients undergoing Burzynski’s treatment, their advanced cancer itself runs secondary to the constant barrage of skepticism coming not only from their local oncologists, but also from friends and family who feel their loved ones are making suspect treatment decisions—even though mainstream oncology has already left many for dead.

As the story unfolds, you will observe a real-time change of hearts and minds from many of these doctors and families. Unlike the first documentary, Part II showcases interviews with board-certified oncologists, surgeons and neurosurgeons, who witnessed patients leave their care, soon to return in great health after opting for the Burzynski Clinic.

Since the mapping of the Cancer Genome, Burzynski has pioneered an expansion of his therapy which he calls, “Personalized Gene-Targeted Cancer Therapy”, where each patient’s Genomic Cancer Atlas is mapped and a treatment regimen is personally tailored for each individual patient—vs. the conveyor belt, “one-size-fits-all” approach that current oncology adheres to.

Due to the slow-moving, bureaucratic obstacles enforced on Antineoplastons by America’s FDA, this new expanded “personalized gene-targeted” direction has allowed more patients (who are denied access to Antineoplastons) to benefit from Burzynski’s practice in ways never before thought possible. And yet, still with similar resistance and controversy endured by Burzynski’s Antineoplaston therapy.

The film also takes you to Kurume University in Fukuoka, Japan—where independently designed studies of Antineoplastons have been underway for 27 years—without Dr. Burzynski’s (the inventor’s) involvement or supervision. Learn how this team of Japanese pathologists, oncologists and surgeons have studied these anti-cancer compounds using their own methodologies—resulting in the first ever independently-run randomized controlled clinical trials.

“After twenty-seven years of independently testing Antineoplastons—including randomized clinical trials, we found that Dr. Burzynski was right. It’s obviously not anecdotal anymore.”
– Hideaki Tsuda, MD – 2013, Kurume Medical University, Fukuoka Prefecture, Japan

You will be placed into the turbulent journey of how the industry utilizes its now usurped regulatory agency to both block Antineoplastons’ Phase 3 clinical trial process—and orchestrate a group of “information hit men” (also known as an “Astroturf Campaign”) to pollute all channels of public information in an effort to confuse the public over the truth behind Antineoplastons. This international Astroturf group also engages in the intimidation and harassment of prospective and current terminal cancer patients under Dr. Burzynski’s care.

However, most notable of all—are the earth-shattering events that occurred upon the final days of production of this film—you’ll be left speechless, yet with so much to say, when you witness the story and shocking conclusion to Burzynski: Cancer Is Serious Business, Part II.

“I can’t imagine a world where other people will not have the privilege that I have had—the privilege to have their life saved by a new technology that can cure cancer—it’s terrifying.”

– Laura Hymas – 2013, Glioblastoma Grade IV brain cancer patient, after experiencing a complete remission under Antineoplaston therapy.

Purchase both DVDs

burzynski-dvd-set

Free Shipping Available! Click Here.

We Lost the War on Cancer – Review of Alternative Cancer Therapies

we_lost_the_war_on_cancer

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.

 

Read We Lost the War on Cancer – Review of Alternative Cancer Therapies on your mobile device!

FREE! – $0.99

We Lost the War on Cancer – Review of Alternative Cancer Therapies in Apple App Store icon Google Play App store We Lost the War on Cancer – Review of Alternative Cancer Therapies book icon
Kindle We Lost the War on Cancer – Review of Alternative Cancer Therapies Book icon Barnes and Noble Nook We Lost the War on Cancer – Review of Alternative Cancer Therapies icon